The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. (2012)
Attributed to:
Imaging perfusion deficits and thrombolysis safety and efficacy in acute ischaemic stroke. The Third International
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(12)60768-5
PubMed Identifier: 22632908
Publication URI: http://europepmc.org/abstract/MED/22632908
Type: Journal Article/Review
Volume: 379
Parent Publication: Lancet (London, England)
Issue: 9834
ISSN: 0140-6736